Arash Eghbali1, Austin Dukes1, Karl Toischer2,3, Gerd Hasenfuss2,3, Loren J Field4. 1. Krannert Institute of Cardiology and the Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, 1044 W. Walnut Street, Indianapolis, IN, 46202, USA. 2. Department of Cardiology and Pneumology, Heart Center, Georg-August-University, Goettingen, Germany. 3. DZHK (German Center for Cardiovascular Research) Partner Site Goettingen, Goettingen, Germany. 4. Krannert Institute of Cardiology and the Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, 1044 W. Walnut Street, Indianapolis, IN, 46202, USA. ljfield@iu.edu.
Abstract
PURPOSE OF REVIEW: Many forms of heart disease result in the essentially irreversible loss of cardiomyocytes. The ability to promote cardiomyocyte renewal may be a promising approach to reverse injury in diseased hearts. The purpose of this review is to describe the impact of cardiomyocyte cell cycle activation on cardiac function and structure in several different models of myocardial disease. RECENT FINDINGS: Transgenic mice expressing cyclin D2 (D2 mice) exhibit sustained cardiomyocyte renewal in the adult heart. Earlier studies demonstrated that D2 mice exhibited progressive myocardial regeneration in experimental models of myocardial infarction, and that cardiac function was normalized to values seen in sham-operated litter mates by 180 days post-injury. D2 mice also exhibited markedly improved atrial structure in a genetic model of atrial fibrosis. More recent studies revealed that D2 mice were remarkably resistant to heart failure induced by chronic elevated afterload as compared with their wild type (WT siblings), with a 6-fold increase in median survival as well as retention of relatively normal cardiac function. Finally, D2 mice exhibited a progressive recovery in cardiac function to normal levels and a concomitant reduction in adverse myocardial remodeling in an anthracycline cardiotoxicity model. The studies reviewed here make a strong case for the potential utility of inducing cardiomyocyte renewal as a means to treat injured hearts. Several challenges which must be met to develop a viable therapeutic intervention based on these observations are discussed.
PURPOSE OF REVIEW: Many forms of heart disease result in the essentially irreversible loss of cardiomyocytes. The ability to promote cardiomyocyte renewal may be a promising approach to reverse injury in diseased hearts. The purpose of this review is to describe the impact of cardiomyocyte cell cycle activation on cardiac function and structure in several different models of myocardial disease. RECENT FINDINGS: Transgenic mice expressing cyclin D2 (D2 mice) exhibit sustained cardiomyocyte renewal in the adult heart. Earlier studies demonstrated that D2 mice exhibited progressive myocardial regeneration in experimental models of myocardial infarction, and that cardiac function was normalized to values seen in sham-operated litter mates by 180 days post-injury. D2 mice also exhibited markedly improved atrial structure in a genetic model of atrial fibrosis. More recent studies revealed that D2 mice were remarkably resistant to heart failure induced by chronic elevated afterload as compared with their wild type (WT siblings), with a 6-fold increase in median survival as well as retention of relatively normal cardiac function. Finally, D2 mice exhibited a progressive recovery in cardiac function to normal levels and a concomitant reduction in adverse myocardial remodeling in an anthracycline cardiotoxicity model. The studies reviewed here make a strong case for the potential utility of inducing cardiomyocyte renewal as a means to treat injured hearts. Several challenges which must be met to develop a viable therapeutic intervention based on these observations are discussed.
Authors: Hidehiro Nakajima; Hisako O Nakajima; Klaus Dembowsky; Kishore B S Pasumarthi; Loren J Field Journal: Circ Res Date: 2005-11-23 Impact factor: 17.367
Authors: Kishore B S Pasumarthi; Hidehiro Nakajima; Hisako O Nakajima; Mark H Soonpaa; Loren J Field Journal: Circ Res Date: 2004-12-02 Impact factor: 17.367
Authors: Rutger J Hassink; Kishore B Pasumarthi; Hidehiro Nakajima; Michael Rubart; Mark H Soonpaa; Aart Brutel de la Rivière; Pieter A Doevendans; Loren J Field Journal: Cardiovasc Res Date: 2007-12-12 Impact factor: 10.787
Authors: Shah R Ali; Simon Hippenmeyer; Lily V Saadat; Liqun Luo; Irving L Weissman; Reza Ardehali Journal: Proc Natl Acad Sci U S A Date: 2014-05-29 Impact factor: 11.205
Authors: Olaf Bergmann; Ratan D Bhardwaj; Samuel Bernard; Sofia Zdunek; Fanie Barnabé-Heider; Stuart Walsh; Joel Zupicich; Kanar Alkass; Bruce A Buchholz; Henrik Druid; Stefan Jovinge; Jonas Frisén Journal: Science Date: 2009-04-03 Impact factor: 47.728
Authors: Samuel E Senyo; Matthew L Steinhauser; Christie L Pizzimenti; Vicky K Yang; Lei Cai; Mei Wang; Ting-Di Wu; Jean-Luc Guerquin-Kern; Claude P Lechene; Richard T Lee Journal: Nature Date: 2012-12-05 Impact factor: 49.962